NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Adam SS, McDuffie JR, Lachiewicz PF, et al. Comparative Effectiveness of Newer Oral Anticoagulants and Standard Anticoagulant Regimens for Thromboprophylaxis in Patients Undergoing Total Hip or Knee Replacement [Internet]. Washington (DC): Department of Veterans Affairs (US); 2012 Dec.

Cover of Comparative Effectiveness of Newer Oral Anticoagulants and Standard Anticoagulant Regimens for Thromboprophylaxis in Patients Undergoing Total Hip or Knee Replacement

Comparative Effectiveness of Newer Oral Anticoagulants and Standard Anticoagulant Regimens for Thromboprophylaxis in Patients Undergoing Total Hip or Knee Replacement [Internet].

Show details

APPENDIX BEXCLUDED STUDIES

All citations listed in Table B-1 were reviewed in their full-text version and excluded for the reason indicated. An alphabetical reference list follows the table.

Table B-1. Excluded studies with reasons.

Table B-1

Excluded studies with reasons.

LIST OF EXCLUDED STUDIES

  1. Cohen A, Drost P, Marchant N, et al. The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. Clin Appl Thromb Hemost. 2012;18(6):611–627. [PubMed: 22387582]
  2. Dahl OE. Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen. Clin Appl Thromb Hemost. 2009;15(Suppl 1):17S–24S. [PubMed: 19696041]
  3. Dahl OE, Quinlan DJ, Bergqvist D, et al. A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost. 2010;8(9):1966–75. [PubMed: 20586919]
  4. Diamantopoulos A, Lees M, Wells PS, et al. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb Haemost. 2010;104(4):760–70. [PubMed: 20806107]
  5. Duggan ST, Scott LJ, Plosker GL. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Drugs. 2009;69(13):1829–51. [PubMed: 19719335]
  6. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105(4):721–9. [PubMed: 21225098]
  7. Eriksson BI, Friedman RJ. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost. 2009;15(Suppl 1):25S–31S. [PubMed: 19648146]
  8. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e278S–325S. [PMC free article: PMC3278063] [PubMed: 22315265]
  9. Friedman RJ. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials. Orthopedics. 2011;34(10):795–804. [PubMed: 21956181]
  10. Friedman RJ, Dahl OE, Rosencher N, et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010;126(3):175–82. [PubMed: 20434759]
  11. Friedman RJ, Sengupta N, Lees M. Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban. Expert Rev Pharmacoecon Outcomes Res. 2011;11(3):299–306. [PubMed: 21671699]
  12. Goff T, Kontakis G, Giannoudis PV. Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update. Expert Opin Drug Saf. 2011;10(5):687–96. [PubMed: 21406027]
  13. Gomez-Outes A, Terleira-Fernandez A, Suarez-Gea ML, et al. New oral anticoagulants for thromboprophylaxis after total hip or knee replacement: A meta-analysis and indirect treatment comparisons. Basic and Clinical Pharmacology and Toxicology. 2011;109:34.
  14. Gras J. Edoxaban for the prevention of thromboembolic events after surgery. Drugs Today (Barc) 2011;47(10):753–61. [PubMed: 22076490]
  15. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal. Health Technol Assess. 2009;13(Suppl 2):55–62. [PubMed: 19804690]
  16. Hull RD, Liang J, Brant R. Pooled analysis of trials may, in the presence of heterogeneity inadvertently lead to fragile conclusions due to the importance of clinically relevant variables being either hidden or lost when the findings are pooled. Thromb Res. 2010;126(3):164–5. [PubMed: 20542545]
  17. Imberti D, Dall’Asta C, Pierfranceschi MG. Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med. 2009;4(6):471–7. [PubMed: 19696978]
  18. Jacobs JJ, Mont MA, Bozic KJ, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94(8):746–7. [PMC free article: PMC3326685] [PubMed: 22517391]
  19. Kwong LM. Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data. Vasc Health Risk Manag. 2011;7:461–6. [PMC free article: PMC3148419] [PubMed: 21822393]
  20. Kwong LM. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty. Am J Manag Care. 2011;17(1 Suppl):S22–6. [PubMed: 21517652]
  21. Lazo-Langner A, Hawell J, Kovacs MJ, et al. A systematic review and meta-analysis of proportions of thrombosis and bleeding in patients receiving venous thromboembolism (VTE) prophylaxis after orthopedic surgery (OS). an update. Blood. 2009;114(22)
  22. Lee S, White CM. Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review. Conn Med. 2012;76(1):39–42. [PubMed: 22372178]
  23. Lereun C, Wells P, Diamantopoulos A, et al. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. J Med Econ. 2011;14(2):238–44. [PubMed: 21385145]
  24. Mantha S. Oral factor Xa inhibitors vs. enoxaparin for thromboprophylaxis after joint replacement surgery: A meta-analysis. Journal of Thrombosis and Haemostasis. 2011;9:189.
  25. Maratea D, Fadda V, Trippoli S, et al. Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants. J Thromb Haemost. 2011;9(9):1868–70. [PubMed: 21711443]
  26. Melillo SN, Scanlon JV, Exter BP, et al. Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery. Ann Pharmacother. 2010;44(6):1061–71. [PubMed: 20424181]
  27. Merli G, Spyropoulos AC, Caprini JA. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations. Ann Surg. 2009;250(2):219–28. [PubMed: 19638915]
  28. Miller CS, Grandi SM, Shimony A, et al. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation. Am J Cardiol. 2012 [PubMed: 22537354]
  29. Mont MA, Jacobs JJ, Boggio LN, et al. Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg. 2011;19(12):768–76. [PubMed: 22134209]
  30. Nieto JA, Espada NG, Merino RG, et al. Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: Pool-analysis of phase III randomized clinical trials. Thromb Res. 2012;130(2):183–91. [PubMed: 22425218]
  31. Poultsides LA, Gonzalez Della Valle A, Memtsoudis SG, et al. Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. J Bone Joint Surg Br. 2012;94(1):113–21. [PubMed: 22219258]
  32. Prom R, Spinler SA. The role of apixaban for venous and arterial thromboembolic disease. Ann Pharmacother. 2011;45(10):1262–83. [PubMed: 21954450]
  33. Raskob GE, Gallus AS, Pineo GF, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012;94(2):257–64. [PubMed: 22323697]
  34. Stevenson M, Scope A, Holmes M, et al. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technol Assess. 2009;13(Suppl 3):43–8. [PubMed: 19846028]
  35. Trkulja V, Kolundzic R. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croat Med J. 2010;51(2):113–23. [PMC free article: PMC2867548] [PubMed: 20401953]
  36. Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34(3):243–52. [PubMed: 21332248]
  37. Wolowacz SE. Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery. Expert Rev Pharmacoecon Outcomes Res. 2011;11(1):9–25. [PubMed: 21351853]
  38. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009;101(1):77–85. [PubMed: 19132192]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (850K)
  • Disable Glossary Links

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...